1. Home
  2. CELC vs NOA Comparison

CELC vs NOA Comparison

Compare CELC & NOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • NOA
  • Stock Information
  • Founded
  • CELC 2011
  • NOA 1953
  • Country
  • CELC United States
  • NOA Canada
  • Employees
  • CELC N/A
  • NOA N/A
  • Industry
  • CELC Medical Specialities
  • NOA Meat/Poultry/Fish
  • Sector
  • CELC Health Care
  • NOA Consumer Staples
  • Exchange
  • CELC Nasdaq
  • NOA Nasdaq
  • Market Cap
  • CELC 440.0M
  • NOA 478.5M
  • IPO Year
  • CELC 2017
  • NOA 2006
  • Fundamental
  • Price
  • CELC $51.79
  • NOA $12.32
  • Analyst Decision
  • CELC Strong Buy
  • NOA
  • Analyst Count
  • CELC 6
  • NOA 0
  • Target Price
  • CELC $46.50
  • NOA N/A
  • AVG Volume (30 Days)
  • CELC 2.9M
  • NOA 130.0K
  • Earning Date
  • CELC 08-14-2025
  • NOA 08-13-2025
  • Dividend Yield
  • CELC N/A
  • NOA 2.68%
  • EPS Growth
  • CELC N/A
  • NOA N/A
  • EPS
  • CELC N/A
  • NOA 0.87
  • Revenue
  • CELC N/A
  • NOA $919,386,154.00
  • Revenue This Year
  • CELC N/A
  • NOA $19.66
  • Revenue Next Year
  • CELC N/A
  • NOA $2.65
  • P/E Ratio
  • CELC N/A
  • NOA $14.09
  • Revenue Growth
  • CELC N/A
  • NOA 14.15
  • 52 Week Low
  • CELC $7.58
  • NOA $12.28
  • 52 Week High
  • CELC $53.70
  • NOA $22.08
  • Technical
  • Relative Strength Index (RSI)
  • CELC 92.18
  • NOA 27.97
  • Support Level
  • CELC $38.00
  • NOA $14.54
  • Resistance Level
  • CELC $53.40
  • NOA $16.80
  • Average True Range (ATR)
  • CELC 3.33
  • NOA 0.55
  • MACD
  • CELC 0.92
  • NOA -0.20
  • Stochastic Oscillator
  • CELC 89.44
  • NOA 1.45

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About NOA North American Construction Group Ltd. (no par)

North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.

Share on Social Networks: